Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
JAMA Netw Open. 2022 Jan 4;5(1):e2141633. doi: 10.1001/jamanetworkopen.2021.41633.
Individuals with cancer often have an elevated platelet count at the time of diagnosis. The extent to which an elevated platelet count is an indicator of cancer is unclear.
To evaluate the association of an elevated platelet count with a cancer diagnosis.
DESIGN, SETTING, AND PARTICIPANTS: This nested case-control study included Ontario residents enrolled in the provincial health insurance plan who had 1 or more routine complete blood count (CBC) tests performed between January 1, 2007, and December 31, 2017, with follow-up through December 31, 2018. Case patients were individuals with a new cancer diagnosis during the observation period. Eligible control individuals were cancer free before the date of diagnosis for a case patient to whom they were matched. One case patient was matched to 3 controls based on sex, age, and health care use patterns. Data were analyzed from September 24, 2020, to July 13, 2021.
Case patients and controls were assigned to 1 of 5 exposure groups based on age- and sex-specific platelet count distributions in the control population: very low (≤10th percentile), low (>10th to 25th percentile), medium (>25th to <75th percentile), high (75th to <90th percentile), and very high (≥90th percentile).
Odds ratios (ORs) were estimated for specific cancer sites for each category of platelet count at intervals up to 10 years after a blood test.
Of the 8 917 187 eligible Ontario residents with a routine CBC record available, 4 971 578 (55.8%) were women; the median age at the first CBC was 46.4 years (IQR, 32.5-59.5 years). Among individuals with a routine CBC record available, 495 341 (5.6%) received a diagnosis of first primary cancer during the 10-year observation period. The OR for a solid tumor diagnosis associated with a very high platelet count vs a medium platelet count in the 6-month period before the diagnosis was 2.32 (95% CI, 2.28-2.35). A very high platelet count was associated with colon (OR, 4.38; 95% CI, 4.22-4.54), lung (OR, 4.37; 95% CI, 4.22-4.53), ovarian (OR, 4.62; 95% CI, 4.19-5.09), and stomach (OR, 4.27; 95% CI, 3.91-4.66) cancers. Odds ratios attenuated with increasing time from CBC test to cancer diagnosis.
In this nested case-control study, an elevated platelet count was associated with increased risk of cancer at several sites. Our findings suggest that an elevated platelet count could potentially serve as a marker for the presence of some cancer types.
癌症患者在诊断时常常血小板计数升高。血小板计数升高是否是癌症的指标尚不清楚。
评估血小板计数升高与癌症诊断之间的关联。
设计、设置和参与者:本巢式病例对照研究纳入了安大略省参加省级健康保险计划的居民,这些居民在 2007 年 1 月 1 日至 2017 年 12 月 31 日期间进行了 1 次或多次常规全血细胞计数(CBC)检测,并随访至 2018 年 12 月 31 日。病例患者是在观察期内新诊断出癌症的患者。符合条件的对照患者在与病例患者匹配的病例患者确诊前没有癌症。基于性别、年龄和医疗保健使用模式,为每位病例患者匹配了 3 名对照患者。数据分析于 2020 年 9 月 24 日至 2021 年 7 月 13 日进行。
根据对照人群中血小板计数的年龄和性别特异性分布,病例患者和对照患者被分配到 5 个暴露组之一:极低(≤第 10 百分位)、低(第 10 至 25 百分位)、中(第 25 至<第 75 百分位)、高(第 75 至<第 90 百分位)和极高(≥第 90 百分位)。
在 CBC 检测后长达 10 年的时间内,对每个血小板计数类别与特定癌症部位的比值比(OR)进行了估计。
在有常规 CBC 记录的 8917187 名安大略省合格居民中,有 4971578 名(55.8%)为女性;第一次 CBC 的中位年龄为 46.4 岁(IQR,32.5-59.5 岁)。在有常规 CBC 记录的人群中,有 495341 人(5.6%)在 10 年观察期内被诊断出患有第一原发性癌症。与中值血小板计数相比,在诊断前 6 个月内血小板计数极高与实体瘤诊断相关的 OR 为 2.32(95%CI,2.28-2.35)。极高的血小板计数与结肠癌(OR,4.38;95%CI,4.22-4.54)、肺癌(OR,4.37;95%CI,4.22-4.53)、卵巢癌(OR,4.62;95%CI,4.19-5.09)和胃癌(OR,4.27;95%CI,3.91-4.66)有关。OR 随 CBC 检测到癌症诊断时间的增加而减弱。
在这项巢式病例对照研究中,血小板计数升高与多个部位的癌症风险增加相关。我们的研究结果表明,血小板计数升高可能潜在地作为某些癌症类型存在的标志物。